Professional
Added to YB: 2026-01-16
Pitch date: 2026-01-14
CRMD [neutral]
CorMedix Inc.
-1.13%
current return
Author Info
Pernas Research is a former CIO of a $3.5B fund that now share actionable stock research. Sign up for the newsletter.
Company Info
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
Market Cap
$556.3M
Pitch Price
$7.09
Price Target
N/A
Dividend
N/A
EV/EBITDA
5.99
P/E
3.13
EV/Sales
3.03
Sector
Pharmaceuticals
Category
N/A
Pernas Research Passes On: CorMedix Inc.
CRMD (pass): FDA-approved antimicrobial catheter lock solution, ~70% reduction in bloodstream infections. Revenue scaling to ~$260M in 2025, but stock down 40% YTD as Medicare removes subsidy in 2H26, compressing pricing 50%+. High gross margins should keep EV/EBITDA <10x despite price cuts.
Read full article (1 min)